Pharmaceuticals for Women's Health: Global Markets
Report Scope:
While women’s health encompasses several health issues, this report will focus on menopause-related disorders, postmenopausal osteoporosis, endometriosis, polycystic ovarian syndrome and pregnancy disorders. This report does not focus on drugs for infertility, diagnostic and drug technologies for breast cancer or therapies and diagnostics for ovarian cancer.
Report Includes:
While women’s health encompasses several health issues, this report will focus on menopause-related disorders, postmenopausal osteoporosis, endometriosis, polycystic ovarian syndrome and pregnancy disorders. This report does not focus on drugs for infertility, diagnostic and drug technologies for breast cancer or therapies and diagnostics for ovarian cancer.
Report Includes:
- 54 tables
- Detailed overview of the global markets for pharmaceuticals for women's health and identification of the main women's health disorders
- Analyses of market trends, with data from 2019, estimates for 2020 and projections of compound annual growth rates (CAGRs) through 2025
- Evaluation of the impact of demographic, economic and other factors that will drive future demand in the women's health therapeutics market
- A look at the unmet needs in women’s health therapeutics and details of the promising new drugs and therapies that are still in development and testing stage
- Market forecast of the potential drugs in the pipeline, information on late-stage pipeline drugs and overview of osteoporosis drug development
- Insights into government concerns and initiatives towards women’s health
- Highlights of current and future market potential and a detailed analysis of the current market size, and regulatory scenarios
- Market share analysis of leading drug manufacturers and detailed coverage of women's health therapeutics industry in terms of different events like mergers and acquisitions, agreements, collaborations, and partnerships
- Company profiles of the leading suppliers of the industry including AbbVie Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Johnson & Johnson Inc. and Merck KGaA
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 TECHNOLOGIES AND GLOBAL MARKETS OVERVIEW
Disease Overview and Definitions
Market Driving Factors and Opportunities
Aging Female Population
Government Involvement and Increased Funding
Increasing Awareness Regarding Women's Disorders and Treatments
Market Restraints
Poor Diagnosis
Availability of Alternate Treatment Options and Lifestyle Changes
Unavailability of Novel Treatments
High Cost of Treatment
CHAPTER 4 PIPELINE ASSESSMENT AND ANALYSIS
Drugs in the Pipeline
Overview of Osteoporosis Drug Development Pipeline
Late-Stage Pipeline Drugs
Relugolix (Myovant Sciences)
Proellex (Repros Therapeutics)
CHAPTER 5 REGULATORY STRUCTURE
Overview of Regulations
United States
Canada
Europe
Japan
Overview of Pricing and Reimbursement
United States
Canada
Europe
Japan
CHAPTER 6 MARKET BREAKDOWN BY WOMEN’S HEALTH CONDITION, DISORDER AND DISEASE
Introduction
Menopause
Overview
Symptoms
Risk Factors
Epidemiology and Economic Burden
Diagnosis
Treatments
Market Size and Forecasts
Postmenopausal Osteoporosis
Overview
Epidemiology and Economic Burden
Diagnosis
Treatments
Market Size and Forecasts
Endometriosis
Overview
Epidemiology and Economic Burden
Diagnosis
Treatments
Market Size and Forecasts
Polycystic Ovary Syndrome (PCOS)
Overview
Reducing the Risk of PCOS
Epidemiology and Economic Burden
Diagnosis
Treatments
Market Size and Forecasts
Pregnancy Disorders and Management
Overview
Market Size and Forecasts
Others
Overview
Market Size and Forecasts
CHAPTER 7 MARKET BREAKDOWN BY REGION
Introduction
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Rest of Asia-Pacific
South America
Middle East and Africa
CHAPTER 8 COMPETITIVE LANDSCAPE AND KEY DEVELOPMENTS
Market Players and Strategies
Patent Analysis
Key Patents
Key Developments
Mergers and Acquisitions
Development of Innovative Products/Novel Product Launch
Agreements, Collaborations and Partnerships
Key Products
CHAPTER 9 COMPANY PROFILES
ABBVIE INC.
ALLERGAN PLC
AMGEN INC.
BAYER AG
DAIICHI SANKYO CO. LTD.
ELI LILLY AND CO.
JOHNSON & JOHNSON INC.
MERCK & CO. INC.
MERCK KGAA
NOVO NORDISK
PFIZER INC.
CHAPTER 10 APPENDIX: GLOSSARY AND ACRONYMS
Acronyms Used in the Report
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 TECHNOLOGIES AND GLOBAL MARKETS OVERVIEW
Disease Overview and Definitions
Market Driving Factors and Opportunities
Aging Female Population
Government Involvement and Increased Funding
Increasing Awareness Regarding Women's Disorders and Treatments
Market Restraints
Poor Diagnosis
Availability of Alternate Treatment Options and Lifestyle Changes
Unavailability of Novel Treatments
High Cost of Treatment
CHAPTER 4 PIPELINE ASSESSMENT AND ANALYSIS
Drugs in the Pipeline
Overview of Osteoporosis Drug Development Pipeline
Late-Stage Pipeline Drugs
Relugolix (Myovant Sciences)
Proellex (Repros Therapeutics)
CHAPTER 5 REGULATORY STRUCTURE
Overview of Regulations
United States
Canada
Europe
Japan
Overview of Pricing and Reimbursement
United States
Canada
Europe
Japan
CHAPTER 6 MARKET BREAKDOWN BY WOMEN’S HEALTH CONDITION, DISORDER AND DISEASE
Introduction
Menopause
Overview
Symptoms
Risk Factors
Epidemiology and Economic Burden
Diagnosis
Treatments
Market Size and Forecasts
Postmenopausal Osteoporosis
Overview
Epidemiology and Economic Burden
Diagnosis
Treatments
Market Size and Forecasts
Endometriosis
Overview
Epidemiology and Economic Burden
Diagnosis
Treatments
Market Size and Forecasts
Polycystic Ovary Syndrome (PCOS)
Overview
Reducing the Risk of PCOS
Epidemiology and Economic Burden
Diagnosis
Treatments
Market Size and Forecasts
Pregnancy Disorders and Management
Overview
Market Size and Forecasts
Others
Overview
Market Size and Forecasts
CHAPTER 7 MARKET BREAKDOWN BY REGION
Introduction
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Rest of Asia-Pacific
South America
Middle East and Africa
CHAPTER 8 COMPETITIVE LANDSCAPE AND KEY DEVELOPMENTS
Market Players and Strategies
Patent Analysis
Key Patents
Key Developments
Mergers and Acquisitions
Development of Innovative Products/Novel Product Launch
Agreements, Collaborations and Partnerships
Key Products
CHAPTER 9 COMPANY PROFILES
ABBVIE INC.
ALLERGAN PLC
AMGEN INC.
BAYER AG
DAIICHI SANKYO CO. LTD.
ELI LILLY AND CO.
JOHNSON & JOHNSON INC.
MERCK & CO. INC.
MERCK KGAA
NOVO NORDISK
PFIZER INC.
CHAPTER 10 APPENDIX: GLOSSARY AND ACRONYMS
Acronyms Used in the Report
LIST OF TABLES
Summary Table: Global Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 1: Life Expectancy at Birth, by Region
Table 2: Pipeline Compounds for Endometriosis
Table 3: Pipeline Compounds for Uterine Fibroids
Table 4: Pipeline Compounds for All Other Indications
Table 5: Pipeline Compounds for Osteoporosis
Table 6: Description of Relugolix
Table 7: Description of Proellex
Table 8: Global Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 9: FDA Approved Estrogen-only Medicines
Table 10: FDA-Approved Progestin-Only Medicines
Table 11: FDA Approved Combination Estrogen and Progestin Medicines
Table 12: FDA Approved Combination Estrogen and Hormone Medicines
Table 13: Vagifem (10 mcg), Patent Expiration
Table 14: Global Market for Therapeutics for Menopause, by Region, Through 2025
Table 15: Prolia/XGEVA (Denosumab) Patent Expiration
Table 16: Global Market for Therapeutics for Postmenopausal Osteoporosis, by Region, Through 2025
Table 17: Global Market for Therapeutics for Endometriosis, by Region, Through 2025
Table 18: Global Market for Therapeutics for Polycystic Ovary Syndrome, by Region, Through 2025
Table 19: Global Market for Therapeutics for Pregnancy Disorders and Management, by Region, Through 2025
Table 20: Global Market for Therapeutics for Other Types of Women’s Health Conditions, Disorders and Diseases, by Region, Through 2025
Table 21: Global Market for Therapeutics for Women’s Health Conditions, Disorders and Diseases, by Region, Through 2025
Table 22: North American Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 23: European Market for Therapeutics for Women’s Health, by Condition/Disorder/Disease, Through 2025
Table 24: Asia-Pacific Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 25: South American Market for Therapeutics for Women’s Health, by Condition/Disorder/Disease, Through 2025
Table 26: Middle East and African Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 27: Company Market Share Analysis, by Indication, 2017
Table 28: Tier III Companies
Table 29: Patent Review
Table 30: Marketed Products for Postmenopausal Osteoporosis
Table 31: AbbVie Inc.: Marketed Products
Table 32: AbbVie Inc.: Net Revenue, 2017-2019
Table 33: Allergan Plc: Marketed Products
Table 34: Allergan Plc: Net Revenue, 2017-2019
Table 35: Amgen Inc.: Marketed Products, 2016
Table 36: Amgen Inc.: Net Revenue, 2017-2019
Table 37: Bayer AG: Marketed Products
Table 38: Bayer AG: Net Revenue, 2018 and 2019
Table 39: Daiichi Sankyo Co. Ltd.: Marketed Products
Table 40: Daiichi Sankyo Co. Ltd.: Net Revenue, 2017 and 2018
Table 41: Eli Lilly and Co.: Marketed Products
Table 42: Eli Lilly and Co.: Net Revenue, 2018 and 2019
Table 43: Johnson & Johnson Inc.: Marketed Products, 2020
Table 44: Johnson & Johnson Inc.: Net Revenue, 2017-2019
Table 45: Merck & Co. Inc.: Marketed Products
Table 46: Merck & Co. Inc.: Net Revenue, 2017-2019
Table 47: Merck KGaA: Marketed Products
Table 48: Novo Nordisk: Marketed Products
Table 49: Novo Nordisk: Net Revenue, 2017-2019
Table 50: Pfizer Inc.: Marketed Products by Indication, 2020
Table 51: Pfizer Inc.: Net Revenue, 2017-2019
Table 52: Glossary of Terms Used in Women’s Health Therapeutics
Table 53: Abbreviations Used in Women’s Health Therapeutics
Summary Table: Global Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 1: Life Expectancy at Birth, by Region
Table 2: Pipeline Compounds for Endometriosis
Table 3: Pipeline Compounds for Uterine Fibroids
Table 4: Pipeline Compounds for All Other Indications
Table 5: Pipeline Compounds for Osteoporosis
Table 6: Description of Relugolix
Table 7: Description of Proellex
Table 8: Global Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 9: FDA Approved Estrogen-only Medicines
Table 10: FDA-Approved Progestin-Only Medicines
Table 11: FDA Approved Combination Estrogen and Progestin Medicines
Table 12: FDA Approved Combination Estrogen and Hormone Medicines
Table 13: Vagifem (10 mcg), Patent Expiration
Table 14: Global Market for Therapeutics for Menopause, by Region, Through 2025
Table 15: Prolia/XGEVA (Denosumab) Patent Expiration
Table 16: Global Market for Therapeutics for Postmenopausal Osteoporosis, by Region, Through 2025
Table 17: Global Market for Therapeutics for Endometriosis, by Region, Through 2025
Table 18: Global Market for Therapeutics for Polycystic Ovary Syndrome, by Region, Through 2025
Table 19: Global Market for Therapeutics for Pregnancy Disorders and Management, by Region, Through 2025
Table 20: Global Market for Therapeutics for Other Types of Women’s Health Conditions, Disorders and Diseases, by Region, Through 2025
Table 21: Global Market for Therapeutics for Women’s Health Conditions, Disorders and Diseases, by Region, Through 2025
Table 22: North American Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 23: European Market for Therapeutics for Women’s Health, by Condition/Disorder/Disease, Through 2025
Table 24: Asia-Pacific Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 25: South American Market for Therapeutics for Women’s Health, by Condition/Disorder/Disease, Through 2025
Table 26: Middle East and African Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 27: Company Market Share Analysis, by Indication, 2017
Table 28: Tier III Companies
Table 29: Patent Review
Table 30: Marketed Products for Postmenopausal Osteoporosis
Table 31: AbbVie Inc.: Marketed Products
Table 32: AbbVie Inc.: Net Revenue, 2017-2019
Table 33: Allergan Plc: Marketed Products
Table 34: Allergan Plc: Net Revenue, 2017-2019
Table 35: Amgen Inc.: Marketed Products, 2016
Table 36: Amgen Inc.: Net Revenue, 2017-2019
Table 37: Bayer AG: Marketed Products
Table 38: Bayer AG: Net Revenue, 2018 and 2019
Table 39: Daiichi Sankyo Co. Ltd.: Marketed Products
Table 40: Daiichi Sankyo Co. Ltd.: Net Revenue, 2017 and 2018
Table 41: Eli Lilly and Co.: Marketed Products
Table 42: Eli Lilly and Co.: Net Revenue, 2018 and 2019
Table 43: Johnson & Johnson Inc.: Marketed Products, 2020
Table 44: Johnson & Johnson Inc.: Net Revenue, 2017-2019
Table 45: Merck & Co. Inc.: Marketed Products
Table 46: Merck & Co. Inc.: Net Revenue, 2017-2019
Table 47: Merck KGaA: Marketed Products
Table 48: Novo Nordisk: Marketed Products
Table 49: Novo Nordisk: Net Revenue, 2017-2019
Table 50: Pfizer Inc.: Marketed Products by Indication, 2020
Table 51: Pfizer Inc.: Net Revenue, 2017-2019
Table 52: Glossary of Terms Used in Women’s Health Therapeutics
Table 53: Abbreviations Used in Women’s Health Therapeutics
LIST OF FIGURES
Summary Figure: Global Market for Women’s Health Therapeutics, by Condition/Disorder/Disease 2019-2025
Figure 1: Distribution of Older Population, by Age Group and Sex, 2017
Figure 2: Distribution of Older Population, by Age Group and Sex, 2050
Figure 3: Funding for Research, by Disease, 2014-2016
Figure 4: Funding for Research on Women’s Health, 2014-2016
Figure 5: Insurance Coverage in The U.S., by Type of Healthcare Provider, 2014
Figure 6: Global Market for Women's Health Therapeutics, 2019-2025
Figure 7: Global Market Shares of Women’s Health Therapeutics, by Condition/Disorder/Disease, 2019
Figure 8: Global Market Shares of Women’s Health Therapeutics, by Condition/Disorder/Disease, 2025
Figure 9: Global Market for Therapeutics for Menopause, 2019-2025
Figure 10: Global Market for Therapeutics for Menopause, by Region, 2019-2025
Figure 11: Australian Rate of Hospitalization for Osteoporosis, People Aged 50 and Over, 2015-2016
Figure 12: Global Market for Therapeutics for Postmenopausal Osteoporosis, 2019-2025
Figure 13: Global Market for Therapeutics for Postmenopausal Osteoporosis, by Region, 2019-2025
Figure 14: Global Market for Therapeutics for Endometriosis, 2019-2025
Figure 15: Global Market for Therapeutics for Endometriosis, by Region, 2019-2025
Figure 16: Global Market for Therapeutics for Polycystic Ovary Syndrome, 2019-2025
Figure 17: Global Market for Therapeutics for Polycystic Ovary Syndrome, by Region, 2019-2025
Figure 18: Global Market for Therapeutics for Pregnancy Disorders and Management, 2019-2025
Figure 19: Global Market for Therapeutics for Pregnancy Disorders and Management, by Region, 2019-2025
Figure 20: Global Market for Therapeutics for Other Types of Women’s Health Conditions, Disorders and Diseases, 2019-2025
Figure 21: Global Market for Therapeutics for Other Types of Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 22: Global Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Region, 2019-2025
Figure 23: North American Market for Therapeutics for Women’s Health Conditions, Disorders and Diseases, 2019-2025
Figure 24: North American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 25: North American Market Shares of Therapeutics for Women’s Health, by Condition/Disorder/Disease, 2025
Figure 26: North American Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Country, 2019-2025
Figure 27: U.S. Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 28: Canadian Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 29: Mexican Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 30: European Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 31: European Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 32: European Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
Figure 33: European Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Country, 2019-2025
Figure 34: U.K. Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 35: German Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 36: French Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 37: Spanish Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 38: Italian Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 39: Rest of European Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 40: Asia-Pacific Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 41: Asia-Pacific Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 42: Asia-Pacific Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
Figure 43: Asia-Pacific Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Country, 2019-2025
Figure 44: Chinese Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 45: Japanese Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 46: Indian Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 47: South Korean Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 48: Rest of Asia Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 49: South American Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 50: South American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 51: South American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
Figure 52: Middle East and African Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 53: Middle East and African Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 54: Middle East and African Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
Figure 55: Global Women's Health Therapeutics Market Share Analysis, 2019
Figure 56: AbbVie Inc.: Revenue Share, by Region, 2018
Figure 57: Allergan Plc: Revenue Share, by Business Segment, 2017
Figure 58: Amgen Inc: R&D Expenditures, 2014-2016
Figure 59: Amgen Inc.: Revenue Share, by Region, 2018
Figure 60: Bayer AG: Revenue Share, by Region, 2018
Figure 61: Bayer AG: Revenue Share, by Business Segment, 2018
Figure 62: Daiichi Sankyo Co. Ltd.: R&D Expenditures, 2014-2016
Figure 63: Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018
Figure 64: Eli Lilly and Co.: Revenue Share, by Business Segment, 2018
Figure 65: Eli Lilly and Co.: Revenue Share, by Region, 2018
Figure 66: Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2018
Figure 67: Johnson and Johnson Inc.: Revenue Share, by Region, 2018
Figure 68: Merck & Co. Inc.: Revenue Share, by Business Segment, 2018
Figure 69: Merck & Co. Inc.: Revenue Share, by Region, 2018
Figure 70: Novo Nordisk: Revenue Share, by Region, 2018
Figure 71: Novo Nordisk: Revenue Share, by Business Segment, 2018
Figure 72: Pfizer Inc.: Revenue Share, by Region, 2018
Figure 73: Pfizer Inc.: Revenue Share, by Business Segment, 2018
Summary Figure: Global Market for Women’s Health Therapeutics, by Condition/Disorder/Disease 2019-2025
Figure 1: Distribution of Older Population, by Age Group and Sex, 2017
Figure 2: Distribution of Older Population, by Age Group and Sex, 2050
Figure 3: Funding for Research, by Disease, 2014-2016
Figure 4: Funding for Research on Women’s Health, 2014-2016
Figure 5: Insurance Coverage in The U.S., by Type of Healthcare Provider, 2014
Figure 6: Global Market for Women's Health Therapeutics, 2019-2025
Figure 7: Global Market Shares of Women’s Health Therapeutics, by Condition/Disorder/Disease, 2019
Figure 8: Global Market Shares of Women’s Health Therapeutics, by Condition/Disorder/Disease, 2025
Figure 9: Global Market for Therapeutics for Menopause, 2019-2025
Figure 10: Global Market for Therapeutics for Menopause, by Region, 2019-2025
Figure 11: Australian Rate of Hospitalization for Osteoporosis, People Aged 50 and Over, 2015-2016
Figure 12: Global Market for Therapeutics for Postmenopausal Osteoporosis, 2019-2025
Figure 13: Global Market for Therapeutics for Postmenopausal Osteoporosis, by Region, 2019-2025
Figure 14: Global Market for Therapeutics for Endometriosis, 2019-2025
Figure 15: Global Market for Therapeutics for Endometriosis, by Region, 2019-2025
Figure 16: Global Market for Therapeutics for Polycystic Ovary Syndrome, 2019-2025
Figure 17: Global Market for Therapeutics for Polycystic Ovary Syndrome, by Region, 2019-2025
Figure 18: Global Market for Therapeutics for Pregnancy Disorders and Management, 2019-2025
Figure 19: Global Market for Therapeutics for Pregnancy Disorders and Management, by Region, 2019-2025
Figure 20: Global Market for Therapeutics for Other Types of Women’s Health Conditions, Disorders and Diseases, 2019-2025
Figure 21: Global Market for Therapeutics for Other Types of Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 22: Global Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Region, 2019-2025
Figure 23: North American Market for Therapeutics for Women’s Health Conditions, Disorders and Diseases, 2019-2025
Figure 24: North American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 25: North American Market Shares of Therapeutics for Women’s Health, by Condition/Disorder/Disease, 2025
Figure 26: North American Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Country, 2019-2025
Figure 27: U.S. Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 28: Canadian Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 29: Mexican Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 30: European Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 31: European Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 32: European Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
Figure 33: European Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Country, 2019-2025
Figure 34: U.K. Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 35: German Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 36: French Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 37: Spanish Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 38: Italian Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 39: Rest of European Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 40: Asia-Pacific Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 41: Asia-Pacific Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 42: Asia-Pacific Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
Figure 43: Asia-Pacific Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Country, 2019-2025
Figure 44: Chinese Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 45: Japanese Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 46: Indian Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 47: South Korean Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 48: Rest of Asia Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 49: South American Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 50: South American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 51: South American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
Figure 52: Middle East and African Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 53: Middle East and African Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 54: Middle East and African Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
Figure 55: Global Women's Health Therapeutics Market Share Analysis, 2019
Figure 56: AbbVie Inc.: Revenue Share, by Region, 2018
Figure 57: Allergan Plc: Revenue Share, by Business Segment, 2017
Figure 58: Amgen Inc: R&D Expenditures, 2014-2016
Figure 59: Amgen Inc.: Revenue Share, by Region, 2018
Figure 60: Bayer AG: Revenue Share, by Region, 2018
Figure 61: Bayer AG: Revenue Share, by Business Segment, 2018
Figure 62: Daiichi Sankyo Co. Ltd.: R&D Expenditures, 2014-2016
Figure 63: Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018
Figure 64: Eli Lilly and Co.: Revenue Share, by Business Segment, 2018
Figure 65: Eli Lilly and Co.: Revenue Share, by Region, 2018
Figure 66: Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2018
Figure 67: Johnson and Johnson Inc.: Revenue Share, by Region, 2018
Figure 68: Merck & Co. Inc.: Revenue Share, by Business Segment, 2018
Figure 69: Merck & Co. Inc.: Revenue Share, by Region, 2018
Figure 70: Novo Nordisk: Revenue Share, by Region, 2018
Figure 71: Novo Nordisk: Revenue Share, by Business Segment, 2018
Figure 72: Pfizer Inc.: Revenue Share, by Region, 2018
Figure 73: Pfizer Inc.: Revenue Share, by Business Segment, 2018
